MedExecWomen Invites Women in Life Sciences to Join the 2021 Annual Conference in Boston in October

MedExecWomen, a non-profit organization focused on empowering female executives to accelerate the positive impact of medical devices, diagnostics, drug delivery, and digital healthcare around the world, is hosting the second MedExecWomen Annual Conference for women in the life sciences industry later this month in Boston. This year’s conference will be in person on Oct. 26, 2021, at the Sheraton Boston in Back Bay and registration is now open.

The upcoming conference, Medical Innovation in a Post-Covid World, will be a one-day meeting featuring expert panelists — some of the top physicians and leaders in the life science and medical device industries — discussing the state of the market and several of the biggest ongoing industry challenges and how to overcome them, including:

  • Analyst opinions on the state of the medtech sector
  • COVID changes for how medtech companies lead global organizations and expand commercial operations
  • Where inpatient procedures are going
  • Inequities in healthcare spanning clinical trial participation, patient education and hesitancy, healthcare delivery, and access
  • How to become a board member
  • Ongoing innovation in digital health technologies
  • Healthcare financial pressure due to COVID and ongoing hospital operational practices

“You’ll be joining as many as 150 executive life science women to dig deeper into these important topics and have conversations with experts across the industry,” said Co-founder of MedExecWomen and President and Founder of Medi-Vantage, Maria Shepherd. “There are so many challenges now and into 2022, and we expect even more change in this new normal. In Boston, our medtech expert panelists are going to provide some real insight into what they foresee.”

Full COVID precautions, including masking, ensuring that all registrants are fully vaccinated, and social distancing are being taken to ensure your safety at this important meeting.

Interested in attending? Registration is open at: https://medexecwomen.org/store/p/medexecwomen-annual-conference-2021.

A full agenda is available at: https://medexecwomen.org/2021-agenda.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”